



Biotech Daily

Wednesday July 11, 2012

Daily news on ASX-listed biotechnology companies

- * **ASX FLAT, BIOTECH DOWN:**
 - **SUNSHINE HEART UP 39%, IMPEDIMED DOWN 13%**
- * **REGENEUS CLAIMS FAT-STEM CELL EFFICACY IN MOUSE ARTHRITIS**
- * **SUNSHINE UP 342% ON NASDAQ, 132% ON ASX IN THREE DAYS**
- * **LANG WALKER, COMPANIES TAKE 10% OF QRX**
- * **CALAMA TAKES 5% OF TYRIAN**

MARKET REPORT

The Australian stock market slipped 0.04 percent on Wednesday July 11, 2012 with the S&P ASX 200 down 1.5 points to 4,096.5 points.

Eleven of the Biotech Daily Top 40 stocks were up, 17 fell, seven traded unchanged and five were untraded.

Sunshine Heart was the best for the third trading day in a row, closing up 1.4 cents or 38.9 percent at five cents with 10.2 million shares traded (see below).

Universal Biosensors climbed 6.2 percent; Avita and Phylogica were up more than five percent; Anteo and QRX were up more than four percent; Circadian and Uscom were up more than one percent; with Biota, Cochlear, Heartware and Mesoblast up by less than one percent.

Impedimed led the falls, down three cents or 10.3 percent to 26 cents with 9,000 shares traded.

Both Genetic Technologies and Prima lost 8.7 percent; Cellmid fell 6.7 percent; Alchemia and Neuren fell more than four percent; Clinuvel, Phosphagenics and Viralytics were down more than three percent; Optiscan, Sirtex and Starpharma shed more than two percent; Bionomics, CSL, Living Cell, Reva and Tissue Therapies were down more than one percent; with Acrux and Resmed down by less than one percent.

REGENEUS

Regeneus says it has completed a trial validating the efficacy of its adipose or fat-derived stem cell secretion therapy in a mouse model for rheumatoid arthritis.

Regeneus said the trial results showed a dramatic reduction in the clinical signs of the disease.

The company said the trial was conducted by Tetraq, the commercial arm of the University of Queensland's Centre for Integrated Preclinical Drug Development.

Regeneus said its cell secretion technology was prepared from mixed adipose cell populations which was readily available and contained a rich source of regenerative cells, including mesenchymal stem cells and adipocytes, which worked to reduce inflammation and promote regeneration and repair of tissue.

The company said Tetraq used collagen antibody-induced arthritis, a well-established mouse model of rheumatoid arthritis, to study the effect of two different proprietary adipose-derived cell secretion mixtures.

Regeneus said the trial compared the effect of secretions from a mixture of adipocytes and mesenchymal stem cells to secretions from mesenchymal stem cells alone.

The company said that Macquarie University's director of regenerative science Prof Ben Herbert helped design and manage the trial.

"We administered secretions produced from complex mixtures of cells, including stem cells and adipocytes and observed dramatic reductions in the clinical signs of disease," Prof Herbert said.

"For the secretions from cells that included adipocytes we saw a reduction in the clinical scores to the same level as mice treated with daily corticosteroid positive control," Prof Herbert said.

"These data are a great boost for our research and will be very helpful in designing new trials to demonstrate the efficacy of secretions from mixed cell populations," Prof Herbert said.

Centre for Integrated Preclinical Drug Development executive director Prof Maree Smith said the trial was "aimed at providing important information on the cell secretion technology being developed by Regeneus".

Regeneus said that the trial data would assist in the development of additional trials to further test the clinical efficacy of cell secretion technology.

Regeneus is a public unlisted company based in Sydney.

SUNSHINE HEART

Sunshine Heart climbed as much as 2.9 cents or 131.8 percent to a high of 5.1 cents in three trading days on the ASX.

Despite a 65.8 percent climb on the Nasdaq on Friday on strong volumes, ASX investors were wary on Monday, with just 80,000 shares traded taking the company up 13.6 percent to 2.5 cents.

On Monday night on the Nasdaq, Sunshine Heart was up a further 93.37 percent to \$US9.65, again on strong volumes and ASX investors followed yesterday, taking the stock up as much as 1.9 cents or 76 percent to 4.4 cents before closing up 1.1 cents or 44 percent at 3.6 cents with 6.7 million shares traded.

A third exceptional night on the Nasdaq saw Sunshine Heart up \$US3.65 or 37.82 percent to \$US13.30 with 1.7 million shares traded – a total rise from \$US3.01 of \$10.29 or 341.9 percent in three trading days.

Today on the ASX, Sunshine Heart closed up 1.4 cents or 38.9 percent at five cents with 10.2 million shares traded and a total of 2.8 cents or 127.3 percent in three days.

QRX PHARMA

Lang Walker and three related companies have increased their holding in QRX from 12,017,007 shares (8.33%) to 13,924,954 shares (9.63%).

Lang Walker said the 1,907,947 shares were acquired between November 1, 2011 and July 2, 2012, with the largest single transaction of 670,000 shares acquired on June 19, 2012 for \$1.54 a share and the largest single parcel of 800,000 shares bought on July 2, 2102 for \$560,333 or 70.0 cents a share.

On June 27, 2012, QRX said its Moxduo registration application had been rejected by the US Food and Drug Administration (FDA) and fell as low as 50 cents a share.

The company said it would continue its efforts for US regulatory approval.

In January, the Lang Walker companies, Auckland Trust Co, Werft Pty Ltd, Tessroff Pty Ltd and Langley Alexander Walker, acquired 2,631,587 shares for an average price of \$1.44 a share (BD: Jan 23, 2012).

QRX was up 3.5 cents or 4.6 percent to 80 cents.

TYRIAN DIAGNOSTICS

Calama Holdings acting for the Mambra Super Fund has become a substantial shareholder in Tyrian with the acquisition of 58,153,834 shares or 5.8 percent.

The initial substantial shareholder notice said the shares were acquired \$58,153.85 or 0.1 cents a share.

The notice signed by Calama director David Whiting said that the holding was associated with David and Susan Whiting.

Tyrian was unchanged at 0.1 cents.